Healthcare / Medical DevicesHKSE
$4.80
-0.06 (-1.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-84.8M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-76.7%
↓Gross Margin
67.2%
↑Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+52.0%
FCF CAGR
—
FCF margin
-6.9%
FCF / Net income
0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $95.3M · net income $-38.2M · FCF $-6.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $95.3M | $95.3M | $53.5M | $41.0M | $27.1M |
| Net Income | $-38.2M | $-38.2M | $-104.4M | $-97.5M | $-112.2M |
| EBITDA | $-33.2M | $-33.2M | $-98.2M | $-95.7M | $-110.1M |
| EPS | — | — | -0.44 | -0.41 | -0.49 |
| Gross Margin | 67.2% | 67.2% | 71.8% | 75.8% | 71.3% |
| Operating Margin | -45.2% | -45.2% | -207.5% | -263.1% | -447.0% |
| Net Margin | -40.1% | -40.1% | -195.0% | -238.1% | -413.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.59 | 0.07 | 0.05 |
| Current Ratio | 1.51 | 1.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.6M | $-6.6M | $-84.8M | $-111.0M | $-103.9M |
| Returns | |||||
| ROE | -76.7% | -76.7% | -141.3% | -60.4% | -46.9% |
| Valuation | |||||
| P/B | 23.08 | 23.08 | 26.03 | 27.07 | 16.33 |
| Growth & Yield | |||||
| Revenue Growth | 78.0% | 78.0% | 30.7% | 50.8% | — |
| EPS Growth | — | — | -7.3% | 16.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.44 → n/d
Residual
-0.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.